Today at the Intl. Symposium on ALS/MND check out the latest findings from Sadri-Vakili lab together with Tiziana assessing how DRP1 and tau affect mitochondrial fragmentation in ALS. More info: tinyurl.com/yx9gbz3v #HealeyHope #ALSSymp

The Symposium on ALS/MND poster session on genetics & genomics features work on early markers of disease in familial ALS from Katharine Nicholson, Dr. James Berry, and collaborators at WashU Medicine Neurology & Mayo Clinic Neuro Jacksonville. #HealeyHope #ALSSymp tinyurl.com/y6nnxyy2

A consistent robust treatment effect on CSF biomarkers of neuroinflammation/neuronal injury (reduced) and neuroprotection (increased) was seen in the Phase 3 BrainStorm trial. Important learnings for the entire ALS field! MGH Neurology #alsmndsymp #HealeyHope

Thank you Sabrina Paganoni, MD, PhD Amylyx for presenting positive Centaur phase 2 results at #alsmndsymp with BOTH significant survival and functional benefits seen. Very exciting results for a well designed trial! Thank you to patients and caregivers from the study! MGH Neurology

Exciting new data presented by Sabrina Paganoni, MD, PhD from Amylyx and ENC ALS collaboration to predict a broader ALS population may have an up to 11.5 mo survival benefit from AMX0035! MGH Neurology #alsmndsymp #HealeyHope

In addition, a team from Mass General including Sheena Chew, MD, Sabrina Paganoni, MD, PhD, L M and Katharine Nicholson has a poster on patient-reported outcomes and the ALSFRS-R and ABC scales. Download clinical trial poster abstracts here: tinyurl.com/y3zmocgp

If the ALSFRS-R is the gold standard, it is a chocolate coin in gold foil masquerading as such and someday will be devoured by more objective measures - a patient with a flair for the dramatic #alsmndsymp MGH Neurology Katharine Nicholson

2020 was a turning point for #ALS research- thank you to our supporters and people who inspire our research ⁦I AM ALS⁩ ⁦Sandy Morris⁩ ⁦The ALS Association⁩ ⁦Muscular Dystrophy Association⁩ ⁦MGH Neurology⁩ youtu.be/Qhvl1jEEldg

Coya Therapeutics announces merger with Nicoya Health and close of a $10 million Series A financing. Proceeds will be used to advance Coya's lead therapeutic program, ALS001: an off-the-shelf, autologous, expanded Treg cell therapy for ALS. #ALS bit.ly/36yMrRl

Today, we are excited to share news of our plans to submit a New Drug Submission for AMX0035 for the treatment of #ALS with Health Canada in the first half of 2021. This decision is based on the positive clinical data from the CENTAUR trial, and feedback from Health Canada.

We’re excited to announce our intention to submit a Marketing Authorization Application (MAA) for AMX0035 for the treatment of #ALS to the European Medicines Agency & the start of a Phase 3 trial in Europe & the U.S. bwnews.pr/2RAkHXS

Join us this Friday at 3:30 PM ET for Part 4 of the #ALS Drug Development Webinar Series: Site Considerations conta.cc/3eRQY4I

#ALS #MND MGH Neurology The ALS Association I AM ALS Muscular Dystrophy Association MDA Advocacy ALS ONE

I can't emphasize this enough-the ALS Principles are the boundaries that people living with ALS have needed. 'What we allow will continue' and we must make sure we are building clear paths towards treatments for a horrendous disease, always working together so we get there faster

A big heartfelt thank you to Rep. Jake Auchincloss 🟧 for taking time out of his busy schedule today to meet with me and my family. I truly believe he will do everything in his power to help the ALS community. As I said today WE NEED YOU! Thank you! ❤️

30 signed Lou Gehrig Day baseballs across MLB + a one-of-a kind experience. All net proceeds will benefit the Expanded Access Protocol Program (EAP) at the Sean M. Healey & AMG Center for ALS. The #LouGehrigDay Auction is live now: atmlb.com/3yULkb5

Join Dr. Richard Bedlack dukealsclinic and Dr. Merit Cudkowicz MGH Neurology for Part 6 of the #ALS Drug Development Webinar Series on September 15th conta.cc/3z5Q0v5

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS | Biogen investors.biogen.com/news-releases/…

Stole this from an excellent talk by ⁦Katharine Nicholson⁩ - who can tell me how to have a diet that supplements the things in blue, and suppresses the things in orange?

Exciting to provide clinical and research updates to our patients- from Amylyx and Tofersen to Prevent ALS! youtu.be/kaBwt3YoqsU